The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

Schizophrenia Clinical Trial

Official title:

The Efficacy for Execution Function and Genetic Mechanism of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03772951
• Other study ID #: HKQ201813
• Status: Completed
• Phase: Phase 4
• Start date: January 10, 2019
• Est. completion date: March 31, 2021

Study information

• Verified date: March 2021
• Source: Shanghai Mental Health Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study group received antipsychotic drugs combined with Computerized Cognitive Remediation Therapy (CCRT) for 4 times/week for 45 minutes each time. The control group only received antipsychotic drugs. For a total of 12 weeks. Brain Derived Neurotrophic Factor (BDNF) and Tropomyosin-related kinase B (Trk B) genes in peripheral blood were detected in both groups before and after treatment. Clinical symptoms and executive function assessment were performed in both groups before and after treatment. The relevance of genes and their effects on downstream protein expression levels led to a molecular genetic mechanism for the efficacy of Computerized Cognitive Remediation Therapy (CCRT) .

Description:

Among the cognitive disorders of chronic schizophrenia, the most reported is the executive dysfunction of the prefrontal lobe. There is increasing evidence that Computerized Cognitive Remediation Therapy (CCRT) has a significant improvement in the implementation of schizophrenia, but the specific mechanism is unknown. Therefore, this study plans to select 154 patients with chronic schizophrenia who were hospitalized for a long time. They were randomly divided into two groups. The study group received antipsychotic drugs combined with Computerized Cognitive Remediation Therapy (CCRT) for 4 times/week for 45 minutes each time. The control group only received antipsychotic drugs. For a total of 12 weeks. brain-derived neurotrophic factor (BDNF) and tyrosine receptor kinase B(TRK-B) genes in peripheral blood were detected in both groups before and after treatment. Clinical symptoms and executive function assessment were performed in both groups before and after treatment. The relevance of genes and their effects on downstream protein expression levels led to a molecular genetic mechanism for the efficacy of Computerized Cognitive Remediation Therapy (CCRT).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 154
• Est. completion date: March 31, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Age 18-45 years old, Han nationality, male or female;

2. Comply with the American Diagnostic Criteria for Mental Disorder (DSM-V) diagnostic criteria for "schizophrenia";

3. The course of the disease and continued treatment with antipsychotic drugs for > 2 years, stable for at least one month;

4. Positive NegativeSyndrome Scale (PANSS) < 70 points;

5. intelligence quotient (IQ)>80;

6. Cultural, social and educational backgrounds are sufficient to understand informed consent and research content.

Exclusion Criteria:

1. Concomitant diagnosis in addition to Diagnostic and Statistical Manual of Mental Disorders-V other than schizophrenia;

2. Central nervous system organic diseases;

3. There are alcohol or other substances dependent or abused in the past two months, causing significant social and cognitive impairment;

4. In the past year, there have been major life events such as widowhood;

5. Those who have serious suicide attempts (the third item of the (Hamilton Depression Scale-17,HAMD-17) scale "suicide" = 3 points);

6. The current patient's severe unstable physical disease;

7. pregnant women and lactating women;

8. Those who have received modified electroconvulsive therapy (MECT) and repetitive Transcranial Magnetic Stimulation (rTMS) treatment in the past month;

9. Those who have been ineffective for more than 3 months of systemic psychotherapy.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Other:
• Cognitive Remediation Therapy
Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.

Drug:
• Clozapine
the course of disease is more than 2 years, the condition is stable for more than one month

Locations

Country	Name	City	State
China	Huangpu District Mental Health Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The score of Positive and Negative Syndrome Scale (PANSS)	The score of Positive and Negative Syndrome Scale (PANSS) ranges from 19-133 and will be administered to assess the effectiveness of treatment. Do higher values represent a worse outcome. The subscales are summed to compute a total score.	the baseline
Primary	The score of Positive and Negative Syndrome Scale (PANSS)	The score of Positive and Negative Syndrome Scale (PANSS) ranges from 19-133 and will be administered to assess the effectiveness of treatment. Do higher values represent a worse outcome.The subscales are summed to compute a total score.	the end of 12 week
Primary	The concentration of Brain Derived Neurotrophic Factor (BDNF) used to assess the effectiveness of treatment	The Concentration of Brain Derived Neurotrophic Factor (BDNF) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.	the baseline
Primary	The concentration of Brain Derived Neurotrophic Factor (BDNF) used to assess the effectiveness of treatment	The Concentration of Brain Derived Neurotrophic Factor (BDNF) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.	the end of 12 week
Secondary	The concentration of tyrosine receptor kinase B(TRK-B) used to assess the effectiveness of treatment	The Concentration of tyrosine receptor kinase B(TRK-B) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.	the baseline
Secondary	The concentration of tyrosine receptor kinase B(TRK-B) used to assess the effectiveness of treatment	The Concentration of tyrosine receptor kinase B(TRK-B) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.	the end of 12 week